The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
The role of PCA3 testing in a homogenenous population of patients with low and intermediate-risk prostate cancer treated with brachytherapy.
Ana Medina
No relevant relationships to disclose
Raquel Losada
No relevant relationships to disclose
Alfonso Mariño
No relevant relationships to disclose
Arturo Candal Gómez
No relevant relationships to disclose
Inmaculada Diaz
No relevant relationships to disclose
Manuel Ramos Vazquez
No relevant relationships to disclose
Jose Luis Fernandez
No relevant relationships to disclose
Sonia Aranzazu Garcia
No relevant relationships to disclose
Carlos Mendez
No relevant relationships to disclose
Cristina Azpitarte
No relevant relationships to disclose
Lorena Paris
No relevant relationships to disclose
Venancio Chantada Abal
No relevant relationships to disclose
Sara Martinez Breijo
No relevant relationships to disclose
Luis M. Antón Aparicio
No relevant relationships to disclose
David Olmos
No relevant relationships to disclose